Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.

Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ.

J Clin Psychopharmacol. 2014 Apr;34(2):199-204. doi: 10.1097/JCP.0000000000000071.

PMID:
24525659
2.

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.

Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group.

Am J Psychiatry. 2004 Jun;161(6):975-84.

PMID:
15169685
3.
5.

In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.

Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW.

Xenobiotica. 2010 Nov;40(11):721-9. doi: 10.3109/00498254.2010.512670.

PMID:
20937004
6.

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA.

Am J Psychiatry. 2008 Nov;165(11):1420-31. doi: 10.1176/appi.ajp.2008.08050756. Epub 2008 Sep 15. Erratum in: Am J Psychiatry. 2008 Nov;165(11):1495.

PMID:
18794207
7.

A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.

Schmidt ME, Kent JM, Daly E, Janssens L, Van Osselaer N, Hüsken G, Anghelescu IG, Van Nueten L.

Eur Neuropsychopharmacol. 2012 Oct;22(10):721-33. doi: 10.1016/j.euroneuro.2012.02.007. Epub 2012 Mar 31.

PMID:
22464973
8.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
9.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
10.

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.

Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M.

J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):60-70. doi: 10.1097/CHI.0b013e3181900404.

PMID:
19057413
11.

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.

Kramer MS, Last B, Getson A, Reines SA.

Arch Gen Psychiatry. 1997 Jun;54(6):567-72. Erratum in: Arch Gen Psychiatry 1997 Dec;54(12):1080.

PMID:
9193198
12.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

13.

Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.

Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R; Abordaje Síntomas Negativos Esquizofrenia Group.

J Clin Psychiatry. 2014 Jun;75(6):608-15. doi: 10.4088/JCP.13m08551.

PMID:
25004184
14.

Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.

Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando ML, Senthilal S.

Schizophr Res. 2007 Nov;96(1-3):146-55. Epub 2007 Aug 29.

PMID:
17728106
15.

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.

Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.

J Psychiatr Res. 2006 Oct;40(7):669-76. Epub 2006 Jun 9.

PMID:
16762371
16.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
17.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
18.

The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.

Schoemaker JH, Jansen WT, Schipper J, Szegedi A.

J Clin Psychopharmacol. 2014 Apr;34(2):190-8. doi: 10.1097/JCP.0000000000000073.

PMID:
24525661
19.

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.

Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM.

Am J Psychiatry. 2005 Oct;162(10):1879-87.

PMID:
16199834
20.

Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.

Kane JM, Yang R, Youakim JM.

Schizophr Res. 2012 Mar;135(1-3):116-22. doi: 10.1016/j.schres.2011.11.006. Epub 2011 Dec 16.

PMID:
22178084

Supplemental Content

Support Center